|
1
|
Jemal A, Siegel R, Ward E, Hao Y, Xu J and
Thun MJ: Cancer statistics, 2009. CA Cancer J Clin. 59:225–249.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Patnaik SK, Yendamuri S, Kannisto E,
Kucharczuk JC, Singhal S and Vachani A: MicroRNA expression
profiles of whole blood in lung adenocarcinoma. PLoS One.
7:e460452012. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Zaatar AM, Lim CR, Bong CW, et al: Whole
blood transcriptome correlates with treatment response in
nasopharyngeal carcinoma. J Exp Clin Cancer Res. 31:762012.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Isaksson HS, Sorbe B and Nilsson TK: Whole
blood RNA expression profiles in ovarian cancer patients with or
without residual tumors after primary cytoreductive surgery. Oncol
Rep. 27:1331–1335. 2012.PubMed/NCBI
|
|
5
|
Du YZ, Gu XH, Li L and Gao F: The
diagnostic value of circulating stanniocalcin-1 mRNA in non-small
cell lung cancer. J Surg Oncol. 104:836–840. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Rotunno M, Hu N, Su H, et al: A gene
expression signature from peripheral whole blood for stage I lung
adenocarcinoma. Cancer Prev Res (Phila). 4:1599–1608. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Ji P, Diederichs S, Wang W, et al:
MALAT-1, a novel noncoding RNA and thymosin beta4 predict
metastasis and survival in early-stage non-small cell lung cancer.
Oncogene. 22:8031–8041. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Lin R, Maeda S, Liu C, Karin M and
Edgington TS: A large noncoding RNA is a marker for murine
hepatocellular carcinomas and a spectrum of human carcinomas.
Oncogene. 26:851–858. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Tripathi V, Shen Z, Chakraborty A, et al:
Long noncoding RNA MALAT1 controls cell cycle progression by
regulating the expression of oncogenic transcription factor B-MYB.
PLoS Genet. 9:e10033682013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Szymanski M, Barciszewska MZ, Erdmann VA
and Barciszewski J: A new frontier for molecular medicine:
Noncoding RNAs. Biochim Biophys Acta. 1756:65–75. 2005.PubMed/NCBI
|
|
11
|
Hutchinson JN, Ensminger AW, Clemson CM,
Lynch CR, Lawrence JB and Chess A: A screen for nuclear transcripts
identifies two linked noncoding RNAs associated with SC35 splicing
domains. BMC Genomics. 8:392007. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Guo F, Li Y, Liu Y, Wang J, Li Y and Li G:
Inhibition of metastasis-associated lung adenocarcinoma transcript
1 in CaSki human cervical cancer cells suppresses cell
proliferation and invasion. Acta Biochim Biophys Sin (Shanghai).
42:224–229. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Tano K, Mizuno R, Okada T, Rakwal R,
Shibato J, Masuo Y, Ijiri K and Akimitsu N: MALAT-1 enhances cell
motility of lung adenocarcinoma cells by influencing the expression
of motility-related genes. FEBS Lett. 584:4575–4580. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Lai MC, Yang Z, Zhou L, Zhu QQ, Xie HY,
Zhang F, Wu LM, Chen LM and Zheng SS: Long non-coding RNA MALAT-1
overexpression predicts tumor recurrence of hepatocellular
carcinoma after liver transplantation. Med Oncol. 29:1810–1816.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Xie H, Ma H and Zhou D: Plasma HULC as a
promising novel biomarker for the detection of hepatocellular
carcinoma. Biomed Res Int. 2013:1361062013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Arita T, Ichikawa D, Konishi H, et al:
Circulating long non-coding RNAs in plasma of patients with gastric
cancer. Anticancer Res. 33:3185–3193. 2013.PubMed/NCBI
|
|
17
|
Sun Y, Wang Z and Zhou D: Long non-coding
RNAs as potential biomarkers and therapeutic targets for gliomas.
Med Hypotheses. 81:319–321. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Passtoors WM, Beekman M, Deelen J, et al:
Gene expression analysis of mTOR pathway: Association with human
longevity. Aging Cell. 12:24–31. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Olmos D, Brewer D, Clark J, et al:
Prognostic value of blood mRNA expression signatures in
castration-resistant prostate cancer: A prospective, two-stage
study. Lancet Oncol. 13:1114–1124. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Ross RW, Galsky MD, Scher HI, et al: A
whole-blood RNA transcript-based prognostic model in men with
castration-resistant prostate cancer: A prospective study. Lancet
Oncol. 13:1105–1113. 2012. View Article : Google Scholar : PubMed/NCBI
|
